6 days Ago By Defense World Staff
Wellington Management Group LLP bought a new position in shares of Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH – Free Report ) (TSE:AUP) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 60,751 shares of the biotechnology company’s stock, valued at approximately $546,000.
Several other large investors also recently modified their holdings of AUPH. State Street Corp lifted its holdings in shares of Aurinia Pharmaceuticals by 2.3% during the third quarter.
State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock worth $21,587,000 after buying an additional 64,949 shares in the last quarter. Vanguard Group Inc. raised its position in Aurinia Pharmaceuticals by 6.
9% during the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock valued at $15,535,000 after purchasing an additional 112,113 shares in the last quarter.
Arrowstreet Capital Limited Partnership bought a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter worth $9,662,000. JPMorgan Chase & Co. boosted its stake in shares of Aurinia Pharmaceuticals by 84.
4% in the 4th quarter. JPMorgan Chase & Co. now owns 927,298 shares of the biotechnology company’s stock valued at $8,327,000 after purchasing an additional 424,482 shares in the last quarter.
Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Aurinia Pharmaceuticals by 22.5% during the fourth quarter.
Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company’s stock worth $4,997,000 after buying an additional 102,195 shares in the last quarter. 36.
83% of the stock is owned by institutional investors. Wall Street Analysts Forecast Growth Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 27th.
Aurinia Pharmaceuticals Stock Performance Shares of Aurinia Pharmaceuticals stock opened at $7.73 on Tuesday. Aurinia Pharmaceuticals Inc.
has a 1-year low of $4.71 and a 1-year high of $10.67.
The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.
17. The business has a 50-day moving average price of $8.00 and a two-hundred day moving average price of $8.
10. The company has a market cap of $1.06 billion, a P/E ratio of -51.
53 and a beta of 1.20. Insider Buying and Selling In other Aurinia Pharmaceuticals news, CFO Joseph M.
Miller sold 61,859 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.
00. Following the transaction, the chief financial officer now directly owns 633,515 shares of the company’s stock, valued at approximately $5,068,120. This trade represents a 8.
90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Also, COO Matthew Maxwell Donley sold 65,902 shares of the business’s stock in a transaction that occurred on Monday, March 3rd.
The stock was sold at an average price of $8.00, for a total value of $527,216.00.
Following the sale, the chief operating officer now directly owns 739,456 shares of the company’s stock, valued at $5,915,648. This represents a 8.18 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Insiders have sold a total of 343,898 shares of company stock valued at $2,753,094 over the last ninety days. 4.
30% of the stock is owned by corporate insiders. Aurinia Pharmaceuticals Company Profile ( Free Report ) Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd. Featured Articles Five stocks we like better than Aurinia Pharmaceuticals NYSE Stocks Give Investors a Variety of Quality Options Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Unveiling The Power Of VWAP: A Key Indicator For Traders Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold How to Calculate Return on Investment (ROI) 3 Hot New IPOs Defying the 2025 Market Slump Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc.
( NASDAQ:AUPH – Free Report ) (TSE:AUP). Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
